Q-omics provides the consensus-scored HEXIM1 profile across patient tissues and cancer cell-line models. HEXIM1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HEXIM1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, HEXIM1 protein abundance shows 21,132 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where HEXIM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEXIM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEXIM1 survival associations across molecular data types. HEXIM1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEXIM1 RNA expression–survival associations across cancer types. High HEXIM1 expression shows unfavorable associations in UVM, LAML, HNSC and ACC, but favorable associations in BRCA and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HEXIM1 RNA expression.
This table summarizes HEXIM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HEXIM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEXIM1 shows lower tumor expression in COAD, KICH and READ and higher tumor expression in BRCA, HNSC and CHOL. The COAD box plot shows higher HEXIM1 RNA expression in normal versus tumor tissue (log2 FC = −0.739, t-test p < 0.001).
This table shows molecular features associated with HEXIM1 in patient tissues and cancer cell lines. In patient samples, HEXIM1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HEXIM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
